US4976341051 - Common Stock
NASDAQ:KRBP (12/6/2022, 7:00:03 PM)0 (-0.2%)
|GICS Sector||Health Care|
|Earnings (Last)||08-12 2022-08-12/amc||Earnings (Next)||03-09 2023-03-09|
|Ins Owners||6.56%||Inst Owners||1.68%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
KIROMIC BIOPHARMA INC
7707 Fannin St., Suite 140
Houston TEXAS 77054
CEO: Maurizio Chiriva-Internati
San Diego, CA -- (SBWIRE) -- 11/09/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Kiromic BioPharma, Inc..
/PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP)...
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP)...
Here you can normally see the latest stock twits on KRBP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.